Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 2, 2001, Pages 35-40

  Czekalla, J ^a   Kollack Walker, S ^a   Beasley C M , Jr ^a  

^a Lilly Germany   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG SAFETY; ELECTROCARDIOGRAM; HEART DEATH; HEART DISEASE; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; ARRHYTHMIA; BENZODIAZEPINES; DEATH, SUDDEN; FEMALE; HUMANS; LONG QT SYNDROME; MALE; PIRENZEPINE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TORSADES DE POINTES;

EID: 0035121517     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Sudden death during treatment with phenothiazine derivatives
2. The effect of thioridazine hydrochloride and chlorpromazine on the electrocardiogram
3. Electrocardiographic changes in patients receiving neuroleptic medication
4. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
5. An analysis of the time relations of electrocardiograms
6. How to measure the QT interval: What is normal?
7. Association between QT interval and coronary disease in middle-aged and elderly men: The Zutphen study
8. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia
9. Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes
10. QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drug development
11. Considerations sur l'electrocardiogramme de la fibrillation ventriculaire
12. The pre-clinical assessment of QT interval prolongation: A comparison of in vitro and in vivo methods
13. Atypical antipsychotic agents: A critical review
14. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans
15. Treatment of schizophrenia and delusional disorder in the elderly
16. ECG changes during haloperidol and pimozide treatment of Tourette's disorder
17. Droperidol causes a dose-dependent prolongation of the QT interval
18. Torsades de pointes associated with intravenous haloperidol in critically ill patients
19. Iatrogenic torsade de pointes induced by thioridazine
20. Thioridazine-induced torsades de pointes: Successful therapy with isoproterenol
21. Transient cardiac pacing is insufficiently used to treat arrhythmia associated with thioridazine
22. Phenothiazine death: An unusual case report
23. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics
24. Chlorpromazine induced T wave and QT alternans: A case report and review
25. Torsade de pointes with T wave alternans in a patient receiving moderate dose of chlorpromazine: Report of a case
26. Comparison of T-wave changes in the dog following intravenous administration of chlorpromazine and fluphenazine
27. High doses of fluphenazine enanthate in schizophrenia
28. Sudden death in phenothiazine therapy: A clinico-pathologic study of 12 cases
29. Antipsychotic agents and QT changes
30. Case report: Reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication
31. Cardiovascular effects of droperidol during enflurane and enfluarne-nitrous oxide anaesthesia in man
32. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: A review of the literature
33. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction
34. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill
35. Torsade de pointes and low-dose oral haloperidol
36. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients
37. Significantly higher plasma haloperidol level during co-treatment with carbamazepine may herald cardiac change
38. Life-threatening ventricular arrhythmia (torsade de pointes) after haloperidol overdose
39. Haloperidol-induced torsade de pointes
40. Acute accidental overdosage of haloperidol in children
41. Prolonged Q-T interval and hypokalemia caused by haloperidol
42. Torsades de pointes secondary to intravenous haloperidol after coronary bypass
43. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
44. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia
45. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics
46. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
47. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
48. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
49. ECG changes developing during clozapine treatment
50. Cardiomyopathy associated with clozapine
51. Clozapine induced atrial fibrillation
52. Clozapine and sudden death
53. Heart rate variability in schizophrenic patients and changes of autonomic heart rate parameters under treatment with clozapine
54. Fatal cardiac event following initiation of risperidone therapy
55. A case of risperidone overdose in early schizophrenia: A review of potential complications
56. EPOS: Increasing our understanding of the treatment of schizophrenia
57. The atypical antipsychotic sertindole: A case series
58. Safety concerns over antipsychotic drug, sertindole
59. A review of the safety and tolerability of sertindole
60. Safety of olanzapine
61. Olanzapine overdose
62. Olanzapine overdose with serum concentrations
63. Overdose profiles of new antipsychotic agents
64. Quetiapine: A new atypical antipsychotic
65. Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders
66. Acute quetiapine poisoning
67. QT interval prolongation associated with quetiapine (Seroquel) overdose
68. Cardiac safety profile of olanzapine based on preclinical and clinical ECG data
69. Olanzapine versus placebo in the treatment of acute mania
70. Effects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between amisulpride, olanzapine, sertindole, and clozapine
71. Abnormalities of the QT interval in primary autonomic failure